DENVER--(BUSINESS WIRE)--May 8, 2006--Ceragenix Pharmaceuticals, Inc. today announced that in vitro testing performed by MBEC BioProducts (www.mbec.ca) has shown that its Ceragenin(TM) compound, CSA-13, was over 100 fold more effective in eradicating a methicillin resistant Staphylococcus aureus (MRSA) biofilm than vancomycin. Biofilms are slime-like colonies of bacteria that are responsible for many of the nearly one million medical device related infections each year and are believed to be responsible for approximately 65 percent of chronic infections.
